Journal of Vascular and Interventional Radiology
Volume 20, Issue 7, Supplement , Pages S425-S434 , July 2009

Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria

  • Daniel B. Brown, MD

      Affiliations

    • Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
    • Corresponding Author InformationAddress correspondence to D.B.B., Division of Cardiovascular and Interventional Radiology, Thomas Jefferson University Hospital, Suite 4200 Gibbon Building, 111 South 11th St, Philadelphia, PA 19107
    • ,
  • Jennifer E. Gould, MD

      Affiliations

    • Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
    • ,
  • Debra A. Gervais, MD

      Affiliations

    • Department of Radiology, Gastrointestinal/Genitourinary Division, Massachusetts General Hospital, Boston, Massachusetts
    • ,
  • S. Nahum Goldberg, MD

      Affiliations

    • Department of Radiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
    • ,
  • Ravi Murthy, MD

      Affiliations

    • Division of Diagnostic Imaging, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • Steven F. Millward, MD

      Affiliations

    • Department of Diagnostic Imaging, Peterborough Regional Health Centre, Omemee, Ontario, Canada
    • ,
  • William S. Rilling, MD

      Affiliations

    • Department of Vascular and Interventional Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Jean-Francois S. Geschwind, MD

      Affiliations

    • Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins Hospital, Baltimore, Maryland
    • ,
  • Riad Salem, MD, MBA

      Affiliations

    • Division of Interventional Radiology, Northwestern Memorial Hospital, Chicago, Illinois
    • ,
  • Suresh Vedantham, MD

      Affiliations

    • Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
    • ,
  • John F. Cardella, MD

      Affiliations

    • Department of Radiology, Baystate Health System/Tufts University School of Medicine, Springfield, Massachusetts
    • ,
  • Michael C. Soulen, MD

      Affiliations

    • Section of Interventional Radiology, Department of Radiology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
    • ,
  • Society of Interventional Radiology Technology Assessment Committee and the International Working Group on Image-Guided Tumor Ablation

References 

  1. Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2005;16:765–778
  2. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–1171
  3. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepato-cellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–1739
  4. Brown KT, Nevins AB, Getrajdman GI, et al. Particle embolization for hepatocellular carcinoma. J Vasc Interv Radiol. 1998;9:822–828
  5. Brown KT, Koh BY, Brody LA, et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol. 1999;10:397–403
  6. Stokes K, Stuart K, Clouse M. Hepatic arterial chemoembolization for meta-static endocrine tumors. J Vasc Interv Radiol. 1993;4:341–345
  7. Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors: a prospective phase II study in 24 patients. Cancer. 1993;71:2624–2630
  8. Murthy R, Xiong H, Nunez R, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol. 2005;16:937–945
  9. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepato-cellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16:1627–1639
  10. Kee ST, Ganguly A, Daniel BL, et al. MR-guided transjugular intrahepatic portosystemic shunt creation with use of a hybrid radiography/MR system. J Vasc Interv Radiol. 2005;16:227–234
  11. Sato KT, Larson AC, Rhee TK, et al. Real-time MRI monitoring of trans-catheter hepatic artery contrast agent delivery in rabbits. Acad Radiol. 2005;12:1342–1350
  12. Brown DB, Cardella JF, Sacks D, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol. 2006;17:225–232
  13. Jolesz FA. Interventional magnetic resonance imaging, computed tomography, and ultrasound. Acad Radiol. 1995;2(suppl):S124–S125
  14. Sanz-Altamira PM, Spence LD, Huber-man MS, et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum. 1997;40:770–775
  15. Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2005;16:1653–1659
  16. Pentecost MJ, Daniels JR, Teitelbaum GP, Stanley P. Hepatic chemoembolization: safety with portal vein thrombosis. J Vasc Interv Radiol. 1993;4:347–351
  17. Kim HC, Chung JW, Lee W, Jae HJ, Park JH. Recognizing extrahepatic collateral vessels that supply hepato-cellular carcinoma to avoid complications of transcatheter arterial chemoembolization. Radiographics. 2005;25(suppl):S25–S39
  18. Miyayama S, Matsui O, Taki K, et al. Extrahepatic blood supply to hepato-cellular carcinoma: angiographic demonstration and transcatheter arterial chemoembolization. Cardiovasc Intervent Radiol. 2006;29:39–48
  19. Zhu Q, Cronin EB, Currier AA, et al. Benign versus malignant breast masses: optical differentiation with US-guided optical imaging reconstruction. Radiology. 2005;237:57–66
  20. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655
  21. Wong CY, Qing F, Savin M, et al. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by (18F)-fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol. 2005;16:1101–1106
  22. Kamel IR, Bluemke DA, Eng J, et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2006;17:505–512
  23. Matsuo N, Uchida H, Nishimine K, et al. Segmental transcatheter hepatic artery chemoembolization with iodized oil for hepatocellular carcinoma: antitumor effect and influence on normal tissue. J Vasc Interv Radiol. 1993;4:543–549
  24. Choi BI, Kim HC, Han JK, et al. Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings. Radiology. 1992;182:709–713
  25. Higuchi T, Kikuchi M, Okazaki M. Hepatocellular carcinoma after trans-catheter hepatic arterial embolization: a histopathologic study of 84 resected cases. Cancer. 1994;73:2259–2267
  26. Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60:1552–1563
  27. Maluccio M, Covey AM, Gandhi R, et al. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J Vasc Interv Radiol. 2005;16:955–961
  28. Mondazzi L, Bottelli R, Brambilla G, et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology. 1994;19:1115–1123
  29. Van Beers B, Roche A, Cauquil P, Jamart J, Pariente D, Ajavon Y. Transcatheter arterial chemotherapy using doxorubicin, iodized oil and Gel-foam embolization in hepatocellular carcinoma. Acta Radiol. 1989;30:415–418
  30. Imaeda T, Yamawaki Y, Seki M, et al. Lipiodol retention and massive necrosis after lipiodol-chemoembolization of hepatocellular carcinoma: correlation between computed tomography and histopathology. Cardiovasc Intervent Radiol. 1993;16:209–213
  31. Kawai S, Tani M, Okamura J, et al. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepato-cellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study) (The Cooperative Study Group for Liver Cancer Treatment of Japan). Semin Oncol. 1997;24(suppl):S6-38-S36-45
  32. Takayasu K, Shima Y, Muramatsu Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology. 1987;163:345–351
  33. Solomon B, Soulen M, Baum R, Haskal Z, Shlansky-Goldberg R, Cope C. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol. 1999;10:793–798
  34. Brown DB, Fundakowski CE, LiskerMelman M, et al. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2004;15:1209–1218
  35. Therasse E, Breittmayer F, Roche A, et al. Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology. 1993;189:541–547
  36. Varela M, Bruix J. Hepatocellular carcinoma in the United States: lessons from a population-based study in Medicare recipients. J Hepatol. 2006;44:8–10
  37. Murthy R, Nunez R, Szklaruk J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics. 2005;25(suppl 1):S41–S55
  38. Burke DR, Lewis CA, Cardella JF, et al. Quality improvement guidelines for percutaneous transhepatic cholangiography and biliary drainage. J Vasc Interv Radiol. 2003;14(suppl):S243–S246
  39. Lewis CA, Allen TE, Burke DR, et al. Quality improvement guidelines for central venous access. J Vasc Interv Radiol. 2003;14(suppl):S231–S235
  40. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–181
  41. Gates J, Hartnell GG, Stuart KE, Clouse ME. Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics. 1999;19:399–414
  42. Takayasu K, Moriyama N, Muramatsu Y, et al. Gallbladder infarction after hepatic artery embolization. AJR Am J Roentgenol. 1985;144:135–138
  43. Kuroda C, Iwasaki M, Tanaka T, et al. Gallbladder infarction following hepatic transcatheter arterial embolization: angiographic study. Radiology. 1983;149:85–89
  44. Kiely JM, Rilling WS, Touzios JG, et al. Chemoembolization in patients at high risk: results and complications. J Vasc Interv Radiol. 2006;17:47–53
  45. Caturelli E, Siena DA, Fusilli S, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue— long-term prospective study. Radiology. 2000;215:123–128
  46. Song SY, Wook Chung J, Koo Han J, et al. Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol. 2001;12:313–320
  47. Geschwind JF, Kaushik S, Ramsey DE, Choti MA, Fishman EK, Kobeiter H. Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. J Vasc Interv Radiol. 2002;13:1163–1166
  48. Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol. 2001;12:321–326
  49. Hirakawa M, Iida M, Aoyagi K, Matsui T, Akagi K, Fujishima M. Gastroduodenal lesions after transcatheter arterial chemo-embolization in patients with hepatocellular carcinoma. Am J Gastroenterol. 1988;83:837–840
  50. Blanchard RJ, Morrow IM, Sutherland JB. Treatment of liver tumors with yttrium-90 microspheres alone. Can Assoc Radiol J. 1989;40:206–210
  51. Liu DM, Salem R, Bui JT, et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol. 2005;16:911–935
  52. Bledin AG, Kantarjian HM, Kim EE, et al. 99mTc-labeled macroaggregated albumin in intrahepatic arterial chemo-therapy. AJR Am J Roentgenol. 1982;139:711–715
  53. Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys. 1995;33:919–924
  54. Kishi K, Sonomura T, Satoh M, et al. Acute toxicity of lipiodol infusion into the hepatic arteries of dogs. Invest Radiol. 1994;29:882–889
  55. Chung JW, Park JH, Im JG, Han JK, Han MC. Pulmonary oil embolism after transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology. 1993;187:689–693
  56. Stangl DK. Bridging the gap between statistical analysis and decision making in public health research. Stat Med. 2005;24:503–511
  57. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient (I. Introduction and design). Br J Cancer. 1976;34:585–612
  58. Fisher B. Clinical trials for the evaluation of cancer therapy. Cancer. 1984;54:2609–2617
  59. Sacks D, Marinelli DL, Martin LG, Spies JB. General principles for evaluation of new interventional technologies and devices. J Vasc Interv Radiol. 2003;14:S391–S394
  60. Begg CB, McNeil BJ. Assessment of radiologic tests: control of bias and other design considerations. Radiology. 1988;167:565–569
  61. Rothmann M, Li N, Chen G, Chi GY, Temple R, Tsou HH. Design and analysis of non-inferiority mortality trials in oncology. Stat Med. 2003;22:239–264
  62. Grunkemeier GL, Starr A. Alternatives to randomization in surgical studies. J Heart Valve Dis. 1992;1:142–151
  63. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118:622–629

 None of the authors have identified a conflict of interest.

 This article first appeared in J Vasc Interv Radiol 2007; 18:1469–1478.

PII: S1051-0443(09)00318-2

doi: 10.1016/j.jvir.2009.04.021

Journal of Vascular and Interventional Radiology
Volume 20, Issue 7, Supplement , Pages S425-S434 , July 2009

Article Tools